Emerging roles of pathogens in Alzheimer disease

Judith Miklossy*

Chronic spirochetal infection can cause slowly progressive dementia, cortical atrophy and amyloid deposition in the atrophic form of general paresis. There is a significant association between Alzheimer disease (AD) and various types of spirochete (including the periodontal pathogen *Treponema* and *Borrelia burgdorferi*), and other pathogens such as *Chlamydia pneumoniae* and herpes simplex virus type-1 (HSV-1). Exposure of mammalian neuronal and glial cells and organotypic cultures to spirochetes reproduces the biological and pathological hallmarks of AD. Senile-plaque-like beta amyloid (Aβ) deposits are also observed in mice following inhalation of *C. pneumoniae* in vivo, and Aβ accumulation and phosphorylation of tau is induced in neurons by HSV-1 in vitro and in vivo. Specific bacterial ligands, and bacterial and viral DNA and RNA all increase the expression of proinflammatory molecules, which activates the innate and adaptive immune systems. Evasion of pathogens from destruction by the host immune reactions leads to persistent infection, chronic inflammation, neuronal destruction and Aβ deposition. Aβ has been shown to be a pore-forming antimicrobial peptide, indicating that Aβ accumulation might be a response to infection. Global attention and action is needed to support this emerging field of research because dementia might be prevented by combined antibiotic, antiviral and anti-inflammatory therapy.

Alzheimer disease (AD) is characterised by a slowly progressive decline of memory and cognition. Alzheimer described the characteristic cortical senile plaques and neurofibrillary tangles in the brain of a 51-year-old woman with presenile dementia (Refs 1, 2). Because the presenile form, with onset before the age of 65, is identical to the most common form of senile dementia, today, the term AD is used for the designation of both presenile and senile cases (Refs 3, 4).

Senile plaques were first described by Blocq and Marinesco (Ref. 5). Redlich (Ref. 6) first observed senile plaques in the brains of two patients with senile dementia. Recently, particularly from the use of the Gallyas silver technique (Ref. 7), neuropil threads or curly fibres were recognised as further characteristic
lesions of AD. Granulovacuolar degeneration is another typical alteration of neurons (Ref. 8). Other important features include neuronal and synaptic loss (Ref. 9). Hirano bodies, reactive astrocytosis and microgliosis.

AD is a form of amyloidosis. The amyloid substance aggregated in the brain is a small, ~4 kDa amyloid beta peptide (Aβ). It is released by β- and γ-secretase cleavage from a larger 120 kDa transmembrane amyloid precursor protein (APP) (Refs 10, 11) and was purified and partially sequenced by Glenner and Wong (Ref. 12). APP exhibits features of a glycosylated cell-surface receptor and was shown to be a phagocyte core protein (Ref. 13). APP is phylogenetically highly conserved and constitutively expressed by various cells other than neurons, including immune cells (Ref. 14). Human platelets, peripheral lymphocytes and leukocytes produce the major isoforms of APP, and after activation, they secrete amyloidogenic Aβ (Refs 15, 16, 17, 18).

Aβ1-42 has a higher ability to aggregate than the shorter Aβ1-40 (Refs 19, 20). Aβ exists in soluble nontoxic monomers, strongly toxic soluble oligomers and in the form of less toxic insoluble fibrils. The soluble oligomers of Aβ1-42 are the most toxic (Refs 21, 22, 23, 24, 25, 26). They form annular or pore-like structures that are indistinguishable from a class of pore-forming bacterial toxins (Refs 24, 25, 27), which cause rapid calcium influx through the targeted cell membranes (Refs 28, 29, 30). Recent in vitro and in vivo studies showed that Aβ is an antimicrobial peptide (AMP) that targets bacterial membranes (Ref. 31). AMPs have proinflammatory activities and have a role in innate immune responses (Ref. 31).

Neurofibrillary tangles and neuropil threads contain paired helical filaments (PHFs) (Refs 32, 33). The major component of PHFs is the microtubule-associated protein tau, which is in a pathological hyperphosphorylated state that abolishes microtubule assembly (Refs 34, 35). Sequestration of peptidyl-prolyl cis/trans isomerase NIMA interacting 1 (PIN1) is one theory that explains the formation of these pathological fibrillar lesions (Ref. 36).

Various hypotheses have been proposed to explain the pathogenesis of AD (Refs 37, 38, 39, 40, 41, 42, 43). A significant proportion of early-onset AD is inherited as an autosomal dominant trait (Ref. 44). Missense mutations of the APP gene located on chromosome 21 (Refs 45, 46) are responsible for 5% of all early-onset familial AD cases (Ref. 44). Presenlin-1 (PS1) gene mutations are most frequent in early-onset familial AD (Refs 37, 47). More than 80 different PS1 missense mutations or amino acid deletions have been identified (Refs 37, 47, 48, 49, 50). Presenlin-2 (PS2) mutations are responsible for another subset of early-onset familial AD (Refs 47, 51). As originally shown by Hardy (Ref. 39), mutations in these pathogenic genes alter the processing of APP and result in an increase in amyloidogenic Aβ1-42 and Aβ1-43 (Refs 50, 52, 53, 54, 55, 56, 57, 58, 59). The epsilon 4 allele of apolipoprotein E (APOE ε4) is an important risk factor for late-onset AD, which also correlates with increased Aβ burden (Ref. 60). Finally, there is an association between AD and polymorphisms of various other genes, which include a growing number of genes, implicated in immune defence mechanisms (Refs 61, 62).

The relation between the two major biological markers of AD, Aβ (Refs 38, 41) and hyperphosphorylated tau (Refs 34, 35), is not clear. Soluble Aβ and tau strongly interact (Ref. 63), and APP is expressed in neurofibrillary tangles (Ref. 64), suggesting that these apparently different pathologies are linked.

Alterations of various neurotransmitters, neuropeptides and hormones are reported to occur in AD (Refs 65, 66, 67, 68). The cholinergic hypothesis is based on the alteration of acetylcholine synthesis, transport and release (Refs 69, 70). Oxidative damage to proteins, lipids and nucleic acids (Refs 71, 72, 73, 74) and mitochondrial dysfunction (Ref. 75) are also significant contributors to the pathogenesis of AD. The role of various metals, including aluminium (Refs 76, 77) and iron (Ref. 78) was proposed several decades ago. Direct modulation of APP processing by metal ions, including Ca2+, Zn2+, Fe2+/Fe3+ and Al3+, suggests that disrupted metal homeostasis also leads to increased APP levels (Ref. 79). The calcium homeostasis hypothesis indicates that sustained deregulation of cytosolic calcium represents the common final pathway for neuronal death in AD (Ref. 80). Dysregulation of ubiquitylation or glycosylation processes (Refs 81, 82) has been shown in AD. Vascular lesions, including cerebral hypoperfusion and disturbed brain
Emerging roles of pathogens in Alzheimer disease

http://www.expertreviews.org/

microcirculation, are also important factors (Refs 83, 84, 85, 86, 87, 88, 89, 90, 91). Factors representing a risk for atherosclerosis (Refs 92, 93), are also risk factors for AD. Early involvement of the olfactory system in AD (Ref. 94) led to the ’olfactory hypothesis’, which suggests that putative pathogenic agents might access the brain by the olfactory pathways (Refs 95, 96, 97). Deregulation of various signalling pathways, apoptosis, cranioencephalic trauma, exercise, environmental and nutritional factors, among others, are also implicated in the pathogenesis of AD.

The critical role of chronic inflammation and the importance of interleukin (IL)-1 signalling in AD is now widely recognised (Refs 98, 99, 100). A series of inflammatory mediators, including cytokines, chemokines, proteases, adhesion molecules, free radicals, pentraxins, prostaglandins, anaphylatoxins and activated complement proteins, is present at the site of cortical lesions in AD (Refs 101, 102, 103). The membrane attack complex (MAC, C5b-9) is also associated with plaques, tangles and neuropil threads (Refs 100, 104). Use of nonsteroidal anti-inflammatory drugs reduces the risk of AD (Refs 105, 106, 107, 108).

Nearly a century ago, Fischer, Alzheimer and their colleagues (Refs 2, 109) discussed the possibility that microorganisms could have a role in the formation of senile plaques. That a slow-acting unconventional infectious agent, acquired at an early age and requiring decades to become active, might be involved in AD was considered by several authors (Refs 110, 111). A growing number of recent observations indicate that infectious agents are involved in the pathogenesis of AD. Here, I review historical and recent observations on infectious agents related to AD and analyse the significance of the association and causal relationship.

Analyses between AD and other age-related chronic inflammatory disorders

Pathogens can produce slowly progressive chronic diseases. Following the pioneering work of Warren and Marshall (Ref. 125), it is today established that Helicobacter pylori causes stomach ulcers. Infectious agents are also linked to atherosclerosis, cardio- and cerebrovascular disorders (Refs 126, 127, 128, 129, 130, 131, 132, 133, 134), chronic lung diseases (Refs 135, 136, 137), inflammatory bowel diseases and neuropsychiatric disorders (Refs 138, 139, 140, 141, 142, 143).

Chlamydia pneumoniae (Refs 126, 127), H. pylori (Refs 128, 129) and several periodontal pathogens, including invasive oral spirochetes (Refs 130, 131) and herpes viruses, have been found in human atherosclerotic lesions. Some of them also enhanced atherosclerosis in experimental animals.
These pathogens were also reported to be associated with AD (Refs 144, 145, 146, 147, 148, 149, 150, 151). Epidemiological studies have confirmed that several of these chronic inflammatory disorders are associated with AD (Refs 152, 153, 154, 155). In addition, they are all linked to periodontal polybacterial disorders, which are primarily caused by Gram-negative bacteria (Refs 156, 157, 158, 159). Spirochetes and herpes viruses are predominant periodontal pathogens (Refs 160, 161, 162, 163), and *C. pneumoniae* is a major upper respiratory tract pathogen. An infectious origin might give a comprehensive explanation of the common cellular and molecular mechanisms, inflammatory processes and common inflammatory gene polymorphisms involved in these chronic inflammatory disorders and AD (Refs 61, 164, 165).

**Evidence for the association of pathogens with AD**

**Spirochetes**

Spirochetes are Gram-negative, helical bacteria, which possess endoflagella, taxonomically distinguishing them from other bacteria. There are over 200 different spirochetal species or phylotypes (Ref. 166). Spirochetes are causative agents of important human diseases such as syphilis, pinta, yaws, bejel, Lyme disease, Vincent angina, relapsing fever, leptospirosis, ulcerative gingivitis and various periodontal disorders (Ref. 167). The major *Borrelia* species causing Lyme disease are *B. burgdorferi*

![Distribution of spirochetes in the atrophic form of general paresis and in the frontal cortex of an Alzheimer disease patient with Lyme neuroborreliosis](expertreviews.org)
Relapsing fever is caused by *B. recurrentis*. Oral spirochetes are predominant periodontal pathogens that are highly prevalent in the population and comprise diverse *Treponema* species (Refs 166, 171). Several are invasive (Refs 172, 173): they include *T. denticola*, *T. socranski*, *T. pectinovorum*, *T. amylovorum*, *T. lecithinolyticum*, *T. maltophilum*, *T. medium* and *T. putidum* (Refs 166, 171, 174). *T. vincentii* causes Vincent angina, a necrotising fusospirochetal disease (Ref. 167).

Because spirochetes are strongly neurotropic (Ref. 167), it was expected that several types of spirochetes, in an analogous way to *T. pallidum*, might cause dementia, plaque- and tangle-like lesions, Aβ deposition and consequently might be involved in the pathogenesis of AD. To detect all types of spirochete, neutral techniques need to be used (Ref. 146). Using dark-field microscopy, spirochetes were detected in the cerebrospinal fluid (CSF), in the blood and in the brain in 14 definite AD cases tested (Table 1). Spirochetes were not found in 13 age-matched controls without any AD-type cortical changes (Ref. 146). Silver-stained helically shaped spirochetes were also detected by electron microscopy. Spirochetes were isolated from the cerebral cortex in these 14 AD cases (Table 1), and in three of them, they were cultivated from the brain in a selective medium for *B. burgdorferi* (Ref. 146). Spirochetes were detected and isolated from the brains of eight additional AD cases derived from another laboratory and in the blood of five living patients with clinically diagnosed AD-type dementia (Ref. 186; Table 1). Four healthy controls did not show spirochetes. Taxonomical analyses showed that the helically shaped microorganisms belong to the order *Spirochaetales* (Ref. 187). To ensure the consistency of these results, the detection of spirochetes was also performed using various other techniques, including histochemistry, dark-field microscopy, atomic force microscopy, electron microscopy and immunoelectron microscopy, immunohistochemistry using spirochete and bacterial peptidoglycan (PGN)-specific antibodies (Refs 146, 147, 149, 186, 187, 176, 175, 188, 189), and detection of specific and nonspecific bacterial DNA (Refs 149, 176). PGN is the building block of the cell wall of Gram-negative and Gram-positive bacteria; however, mycoplasma and chlamydiae lack detectable PGN (Refs 190, 191). The morphology of spirochetes detected by spirochete- or PGN-specific antibodies is identical (Fig. 2; compare also Fig. 7 G and H of Ref. 175). PGN-immunoreactive spirochetes were detected in 32 definite AD cases and in 12 cases with mild or moderate AD-type cortical changes.

Other authors found no evidence of spirochetes in the brains of seven AD cases by dark-field or electron microscopy (Ref. 192). However, spirochetes were observed in the blood of one of 22 living patients with AD-type dementia (Table 1). The spirochete observed by these authors corresponded to the vegetative, regularly spiral form. They suggested that it could correspond to an oral spirochete. Whether the atypical, pleomorphic spirochetal forms, which commonly occur in infected tissues, blood and CSF (Refs 167, 175, 177, 193), were considered by the authors is not clear.

**Periodontal pathogen *Treponemas***

Using molecular and immunological techniques, six of seven periodontal *Treponema* species, namely *T. socranski*, *T. pectinovorum*, *T. denticola*, *T. medium*, *T. amylovorum* and *T. maltophilum*, were identified in the brains of AD patients using species-specific polymerase chain reaction (PCR; Table 1). At least one oral *Treponema* species was present in 14 of 16 AD brains, compared with 4 out of 18 controls (Ref. 147). *T. pectinovorum* and *T. socranski* antigens were observed in 15 of 16 AD brains and in 7 of 18 controls. In the hippocampus and in the frontal cortex. Six different *Treponema* species were detected in one AD patient, five species in four, four or three species each in one AD case, and one species in seven AD brains. Two *Treponema* species were observed in one control and one species in the other three positive controls. These results reinforce previous observations (Ref. 146) and indicate that these periodontal pathogen spirochetes, in an identical way to *T. pallidum* and *B. burgdorferi*, have the ability to invade the brain, persist in the brain, and cause dementia, cortical atrophy and amyloid deposition.

**Borrelia burgdorferi***

The causative agent of Lyme disease is transmitted by the bite of infected ticks (Ref. 170). Neurological complications occur in about 15% of affected
Table 1. Detection of spirochetes in AD

<table>
<thead>
<tr>
<th>Material</th>
<th>Number</th>
<th>Method</th>
<th>AD</th>
<th>Control</th>
<th>Culture</th>
<th>Serology</th>
<th>Refs</th>
</tr>
</thead>
<tbody>
<tr>
<td>All types of spirochete</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Brain</td>
<td>27</td>
<td>DF, HC, IHC Bl, CSF, EM, AFM</td>
<td>14/14</td>
<td>0/13*</td>
<td>14/14</td>
<td>ND (Bl 4/5)</td>
<td>146,187</td>
</tr>
<tr>
<td>Brain</td>
<td>12</td>
<td>DF</td>
<td>8/8</td>
<td>0/4*</td>
<td>8/8</td>
<td>ND</td>
<td>186</td>
</tr>
<tr>
<td>Blood</td>
<td>5</td>
<td>DF, Cult</td>
<td>5/5</td>
<td>ND</td>
<td>ND</td>
<td>ND</td>
<td>186</td>
</tr>
<tr>
<td>Brain</td>
<td>24</td>
<td>DNA-DAPI</td>
<td>20/20</td>
<td>0/4*</td>
<td>ND</td>
<td>ND</td>
<td>176</td>
</tr>
<tr>
<td>Brain</td>
<td>10 b</td>
<td></td>
<td>32/32</td>
<td>0/10*</td>
<td>ND</td>
<td>ND</td>
<td>188,189</td>
</tr>
<tr>
<td>Brain</td>
<td>7</td>
<td>DF, EM</td>
<td>0/7</td>
<td>ND</td>
<td>ND</td>
<td>ND</td>
<td>192</td>
</tr>
<tr>
<td>Blood</td>
<td>28</td>
<td></td>
<td>1/22</td>
<td>0/6</td>
<td>ND</td>
<td>ND</td>
<td>192</td>
</tr>
<tr>
<td><strong>Total brain</strong></td>
<td>102</td>
<td></td>
<td>64/71</td>
<td>0/31*</td>
<td>P = 4.8 \times 10^{-18} \text{ OR = 274} \text{ 95% CI = 32–11 345}</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Peridontal pathogen</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>spirochetes</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Brain</td>
<td>34</td>
<td>PCR, IHC</td>
<td>15/16</td>
<td>6/18</td>
<td>ND</td>
<td>ND</td>
<td>147</td>
</tr>
<tr>
<td><strong>Total brain</strong></td>
<td>34</td>
<td></td>
<td>15/16</td>
<td>6/18</td>
<td>P = 3.6 \times 10^{-4} \text{ OR = 30} \text{ CI = 2.8–1364}</td>
<td></td>
<td></td>
</tr>
<tr>
<td><em>Borrelia burgdorferi</em></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Brain</td>
<td>2</td>
<td>IHC, Cult</td>
<td>1/1</td>
<td>0/1</td>
<td>+</td>
<td>ND</td>
<td>178</td>
</tr>
<tr>
<td>Brain</td>
<td>1</td>
<td>DF, IHC, Cult</td>
<td>1/1</td>
<td>+</td>
<td>ND</td>
<td>199</td>
<td></td>
</tr>
<tr>
<td>Brain</td>
<td>10</td>
<td>EM, IHC, Wbl</td>
<td>0/6</td>
<td>0/4</td>
<td>–</td>
<td>ND</td>
<td>185</td>
</tr>
<tr>
<td>Brain</td>
<td>27 b</td>
<td>Cult, IHC, EM Bl, CSF, ISH, Serol 16SrRNA</td>
<td>3/14*</td>
<td>0/12*</td>
<td>3/14</td>
<td>2/14</td>
<td>146,149</td>
</tr>
<tr>
<td>Brain</td>
<td>1</td>
<td>IHC, Serol</td>
<td>1/1</td>
<td>ND</td>
<td>1/1</td>
<td>146</td>
<td></td>
</tr>
<tr>
<td>Brain</td>
<td>10</td>
<td>PCR, Cult</td>
<td>0/10</td>
<td>–</td>
<td>ND</td>
<td>180</td>
<td></td>
</tr>
<tr>
<td>Brain</td>
<td>30</td>
<td>PCR</td>
<td>0/15</td>
<td>0/15</td>
<td>ND</td>
<td>ND</td>
<td>181</td>
</tr>
<tr>
<td>Brain</td>
<td>34 b</td>
<td>PCR, seq</td>
<td>5/16*</td>
<td>1/18*</td>
<td>ND</td>
<td>ND</td>
<td>147</td>
</tr>
<tr>
<td>Brain</td>
<td>1</td>
<td>PCR</td>
<td>1/1</td>
<td>ND</td>
<td>1/1</td>
<td>179</td>
<td></td>
</tr>
<tr>
<td>Brain</td>
<td>11</td>
<td>PCR, ISH</td>
<td>7/10</td>
<td>0/1</td>
<td>ND</td>
<td>1/1</td>
<td>183, 184</td>
</tr>
<tr>
<td><strong>Total brain</strong></td>
<td>127</td>
<td></td>
<td>19/75</td>
<td>1/52</td>
<td>P = 2.9 \times 10^{-4} \text{ OR = 17} \text{ CI = 2–732}</td>
<td></td>
<td></td>
</tr>
<tr>
<td>All studies detecting</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>spirochetes</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Brain</td>
<td>214</td>
<td></td>
<td>102/143</td>
<td>6/71</td>
<td>P = 1.5 \times 10^{-19} \text{ OR = 26} \text{ CI = 10–80}</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Brain, blood, CSF</td>
<td>247</td>
<td></td>
<td>108/170</td>
<td>6/77*</td>
<td>P = 1.1 \times 10^{-17} \text{ OR = 20} \text{ CI = 8–60}</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Data reviewed in the literature with respect to the detection of all types of spirochetes using neutral techniques and the specific detection of periodontal pathogen Treponemata and Bb. Results of the statistical analysis are given for each group and for all studies together. AD indicates number of AD cases positive for spirochetes / number of AD cases analysed; Control indicates number of control cases positive for spirochetes / number of control cases analysed. AD, Alzheimer disease; Bl, blood; CSF, cerebrospinal fluid; EM, electron microscopy; AFM, atomic force microscopy; DF, dark-field microscopy; HC, histochemistry (Warthin and Starry, Bosma-Steiner silver stain for spirochetes); IHC, immunohistochemistry; ISH, in situ hybridisation; PCR, polymerase chain reaction; Bb, Borrelia burgdorferi; Wbl, Western blot; P is exact value of the significance calculated by Fischer test; OR, odds ratio; CI, 95% confidence interval; +, positive; –, negative; ND, not determined; seq, sequencing.

*Controls without any AD-type changes.
**Cases from previous studies, which were subtracted when the total number of cases of studies was considered.
^Cases with mild or moderate AD-type cortical changes.
\*Where the number of positive controls was zero, in order to calculate the OR and 95% CI, one positive case was added to the control group.
individuals. Dementia and subacute presenile dementia both occur in Lyme disease (Refs 146, 149, 194, 195, 196, 197, 198). *B. burgdorferi* was first detected in the brains of two AD patients (Table 1) by MacDonald and Miranda (Ref. 178) and MacDonald (Ref. 199). This spirochete was detected in the cerebral cortex by dark-field microscopy and with a specific antibody against *Borrelia* species. This species was also detected and cultivated from the brains of three definite AD cases in an initial series of 14 AD cases (Ref. 146). Molecular characterisation, using 16S rRNA gene sequence analysis, identified these spirochetes as *B. burgdorferi sensu stricto* (s.s.) (Ref. 149). Electron microscopy analysis confirmed that these spirochetes possess 10–15 endoflagella typical of *Borrelia* species. Two of the three AD patients had a positive CSF serology for *B. burgdorferi*, and the 31 kDa outer surface protein A (OspA) band, which is highly specific for *B. burgdorferi*, was detected by western blot in these three AD cases (Ref. 149). The pathological changes found in the brain were identical to those occurring in the atrophic...
form of general paresis (Ref. 149). The cortical distribution of spirochetes in masses or colonies was identical to those of senile plaques, and the morphology of individual spirochetes was identical to those of curly fibres (Ref. 149). B. burgdorferi antigens colocalised with Aβ in cortical plaques and in leptomeningeal and cortical arteries containing amyloid deposits. Neurofibrillary tangles were also immunoreactive for B. burgdorferi. OspA and flagellin genes were detected in AD-type lesions using in situ hybridisation (ISH) (Fig. 2b). In additional AD patients with concurrent Lyme neuroborreliosis, B. burgdorferi-specific antigens (Ref. 146) and DNA (Ref. 179) were observed. Using species-specific PCR, B. burgdorferi DNA was detected in 5 of 16 AD patients tested and in 1 of 18 controls, all of which also had oral Treponema spirochetes (Ref. 147). Finally, B. burgdorferi-specific DNA was detected by both ISH and PCR in the hippocampus in 7 of 10 pathologically confirmed AD cases (Refs 183, 184) (Table 1).

Pappolla and colleagues (Ref. 185) failed to detect B. burgdorferi in six AD patients. They stated that they could not exclude other spirochetes not detected by their methods. In all other studies where B. burgdorferi was not detected, evidence is lacking on whether the analysed AD patients had Lyme neuroborreliosis or not (Refs 180, 181) (Table 1). Similarly, the analysis of the serology of B. burgdorferi alone, as a result of the low incidence of Lyme dementia compared with AD, might give false-negative results (Refs 180, 182). To demonstrate the role of B. burgdorferi, AD patients with Lyme neuroborreliosis should be analysed.

Taken together, these observations show that various authors detected and cultivated various types of spirochetes from the brains of AD patients. Coinfection with several types of spirochetes occurs.

**Chlamydia pneumoniae**

Several authors reported the existence of an association between C. pneumoniae, an obligate intracellular respiratory pathogen, and AD (Refs 144, 200, 201, 202, 203) (Table 2). C. pneumoniae-specific DNA was detected in the brains in 90% of sporadic AD patients and in 5% of controls (Ref. 144) (Table 2). Two mRNAs, encoding KDO transferase and a 376 KDa protein, specific to C. pneumoniae, were also identified in frozen AD brain tissue by reverse transcriptase-PCR (RT-PCR).

Immunohistochemical analyses of AD brains showed C. pneumoniae in microglia, perivascular macrophages and astrocytes, and in about 20% of neurons (Refs 144, 200, 201, 203, 207, 211). They were commonly found in brain regions showing the characteristic neuropathology of AD (Refs 144, 200, 201). The presence of C. pneumoniae in the brains of AD patients was also confirmed by immunoelectron microscopy using specific monoclonal antibody against the outer membrane protein of C. pneumoniae. Electron and immunoelectron microscopy identified both chlamydial elementary bodies and reticulate bodies (RBs) (Refs 212, 144). That the replicative RB form was also detected in glial cells, neurons and pericytes indicates that a viable and transcriptionally active form of the microorganism is present in these cells (Refs 201, 213, 214, 215). Pleomorphic forms of C. pneumoniae were also observed (Ref. 213). C. pneumoniae-specific DNA was detected in the CSF in a significantly higher number of cases in AD patients (43.9%) than in controls (10.6%) (Ref. 202). C. pneumoniae was cultured from various brain samples of AD patients originating from different geographic regions of North America (Refs 144, 201, 215) and was also isolated from the CSF (Ref. 202). Tor-1 and Phi-1 isolates were characterised by PCR assays targeting C. pneumoniae-specific genes Cpn0695, Cpn1046 and tyrP. Two groups, using paraffin-embedded brain samples, failed to detect C. pneumoniae in AD or in controls by PCR (Refs 216, 217). In another study, C. pneumoniae was detected in 2 of 15 AD cases and in 1 of 5 controls (Ref. 204).

**Other bacteria**

Propionibacterium acnes, an atypical anaerobic bacterium, was identified in biopsy specimens of the frontal cortex in three of four AD patients and in one of five controls with cerebral tumour. The P. acnes positive control was an elderly patient with cardiovascular risk factors and glioblastoma (Ref. 205). P. acnes was identified by microbiological methods and by gas chromatography. The bacterium was cultivated from frontal cortical biopsy specimens in Schaedler blood agar, at 35°C, under anaerobic conditions (Refs 205, 206). P. acnes has long been considered to be a commensal bacillus of the...
Recent observations showed that *P. acnes*, the causative agent of acne vulgaris, is implicated in various infections, including brain abscesses, endocarditis, endophthalmitis and osteomyelitis (Refs 208, 209). *P. acnes* was also shown to be a predominant periodontal pathogen (Ref. 218). By haematogenous dissemination, it can reach and infect various organs, including the brain. Stabilisation of the clinical symptoms and memory improvement were observed in two AD cases treated with *P. acnes*-sensitive cephalosporine combined with enalapril and oestrogen (Ref. 206). The author pointed to microangiopathy as the underlying pathology (Refs 219, 220). Because the number of AD cases analysed is low, further studies should be encouraged to determine any association of *P. acnes* with AD.

Actinomycetes have also been suggested to be involved in AD, with an incidence four times higher than in other pathological conditions (Ref. 221). Ultrastructural analysis revealed that the fibronectin-immunopositive fibrillary lesions in senile plaques, which were negative for neuronal, glial and macrophage markers, are compatible with filamentous microorganisms and might correspond to *Actinomyces* (Ref. 221). It is noteworthy that *Actinobacillus actinomycetemcomitans* is a frequent periodontal pathogen (Ref. 222) and that *Nocardia asteroides* was reported to cause Parkinson-like symptoms in experimental animals (Ref. 223).

Finally, the causative agent of stomach ulcers, *H. pylori* (Ref. 125), has also been suggested to be associated with AD (Refs 224, 225, 226). Serum IgG and IgA antibodies against *H. pylori* occurred in a higher percentage in the group of 30 AD patients compared with 30 controls (Ref. 224). The difference is statistically significant as determined by post-hoc.

---

**Table 2. Detection of Chlamydophyla pneumoniae and other bacteria in AD**

<table>
<thead>
<tr>
<th>Material</th>
<th>Number</th>
<th>Method</th>
<th>AD</th>
<th>Control</th>
<th>Refs</th>
</tr>
</thead>
<tbody>
<tr>
<td><em>C. pneumoniae</em></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Brain</td>
<td>38</td>
<td>PCR, EM, IHC, RT-PCR, Cult</td>
<td>17/19</td>
<td>1/19</td>
<td>144</td>
</tr>
<tr>
<td></td>
<td>25</td>
<td>PCR, IHC</td>
<td>0/25</td>
<td>0/20</td>
<td>216</td>
</tr>
<tr>
<td></td>
<td>20</td>
<td>PCR, IHC</td>
<td>0/20</td>
<td>0/20</td>
<td>217</td>
</tr>
<tr>
<td></td>
<td>20</td>
<td>PCR, Cult</td>
<td>2/15a</td>
<td>1/5a</td>
<td>204</td>
</tr>
<tr>
<td></td>
<td>21</td>
<td>PCR, ISH</td>
<td>21/21</td>
<td>0/1</td>
<td>200</td>
</tr>
<tr>
<td></td>
<td>52</td>
<td>PCR, Cult, RT-PCR</td>
<td>20/25</td>
<td>3/27</td>
<td>201</td>
</tr>
<tr>
<td>CSF</td>
<td>104</td>
<td>PCR, Cult</td>
<td>25/57</td>
<td>5/47</td>
<td>202</td>
</tr>
<tr>
<td>Total brain</td>
<td>177</td>
<td></td>
<td>60/125</td>
<td>5/52</td>
<td></td>
</tr>
<tr>
<td>P = 4.5 × 10⁻⁷;</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>OR = 8.7; CI = 3.1–29.5;</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Brain and</td>
<td>281</td>
<td></td>
<td>85/182</td>
<td>10/99</td>
<td></td>
</tr>
<tr>
<td>CSF</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>P = 9.8 × 10⁻¹¹;</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>OR = 7.8; CI = 3.7–17.8;</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><em>Propionibacterium acnes</em></td>
<td>3</td>
<td>Cult</td>
<td>3/4</td>
<td>1/5</td>
<td>219, 220</td>
</tr>
<tr>
<td><em>H. pylori</em></td>
<td>Stomach</td>
<td>80</td>
<td>44/50</td>
<td>14/30</td>
<td>225</td>
</tr>
</tbody>
</table>

AD, number of AD cases with positive detection/number of AD cases analysed; Control, number of control cases with positive detection/number of control cases analysed; CSF, cerebrospinal fluid; PCR, polymerase chain reaction; RT-PCR, reverse transcriptase-PCR; EM, electron microscopy; IHC, immunohistochemistry; Cult, culture. P, exact value of significance following Fischer test; OR, odds ratio; CI, 95% confidence interval values.

aPositive in at least one of several samples.
An almost twofold higher prevalence of gastric H. pylori infection was observed in clinically diagnosed AD patients and in patients with mild cognitive decline (Refs 225, 227) than in controls. H. pylori-specific IgG antibody levels were also significantly higher in the blood and CSF of AD patients than in controls (Ref. 226). Additional studies would be of interest in detecting whether H. pylori is present in the brain and to analyse the possibility of a causal relationship between H. pylori and AD.

Herpes simplex virus type-1 (HSV-1) and other viruses

HSV-1 is a common neurotropic virus that infects around 70% of the population after the age of 50 (Refs 150, 228, 229, 230). HSV-1 DNA was detected (Table 2) in brain samples using ISH in some elderly patients with dementia (Ref. 231). Three other studies failed to detect HSV-1 by ISH in AD or in control brains (Refs 232, 233, 234, 235). Increasing numbers of recent observations have detected HSV-1 DNA in the brain in AD (Refs 150, 151, 228, 229, 236, 237, 238). Using PCR, Jamieson et al. (Ref. 150) observed HSV-1 DNA in the brains of a high proportion of elderly subjects, with or without AD, which was absent or less frequent in young controls (Ref. 228). Several authors showed that HSV-1 is a significant risk factor (Table 3) when present in AD patients who are carriers of APOE ε4 (Refs 236, 237, 238), but this is not supported by Beffert et al. (Refs 239, 240). In situ PCR showed that HSV-1 DNA is localised to senile plaques (Ref. 243). Ninety per cent of senile plaques in AD and 80% in normal ageing subjects contained viral DNA (Ref. 241).

### Table 3. Detection of HSV-1 in AD

<table>
<thead>
<tr>
<th>Material</th>
<th>Number</th>
<th>Method</th>
<th>AD</th>
<th>Control</th>
<th>P value</th>
<th>Refs</th>
</tr>
</thead>
<tbody>
<tr>
<td>Brain 6</td>
<td>ISH</td>
<td>2/3</td>
<td>1/3</td>
<td>1/3</td>
<td>0.423</td>
<td>231</td>
</tr>
<tr>
<td>Brain 5</td>
<td>ISH</td>
<td>0/3</td>
<td>0/2</td>
<td>0/2</td>
<td></td>
<td>232</td>
</tr>
<tr>
<td>Brain 23</td>
<td>ISH</td>
<td>0/18</td>
<td>0/5</td>
<td>0/5</td>
<td></td>
<td>233</td>
</tr>
<tr>
<td>Brain 13</td>
<td>ISH</td>
<td>0/8</td>
<td>0/5</td>
<td>0/5</td>
<td></td>
<td>234</td>
</tr>
<tr>
<td>Brain 6</td>
<td>ISH</td>
<td>0/4</td>
<td>0/2</td>
<td>0/2</td>
<td></td>
<td>235</td>
</tr>
<tr>
<td>Brain 14</td>
<td>PCR</td>
<td>8/8</td>
<td>6/6</td>
<td></td>
<td></td>
<td>150</td>
</tr>
<tr>
<td>Brain 36 + 10</td>
<td>PCR</td>
<td>14/21</td>
<td>9/15 (0/5 middle aged; 0/5 young)</td>
<td></td>
<td>228</td>
<td></td>
</tr>
<tr>
<td>Brain 155</td>
<td>PCR</td>
<td>73/98</td>
<td>41/57</td>
<td>0.485</td>
<td>229</td>
<td></td>
</tr>
<tr>
<td>Brain 90</td>
<td>PCR</td>
<td>36/46</td>
<td>28/44</td>
<td></td>
<td>0.295 (P &lt; 0.0001, APOE ε4)</td>
<td>236</td>
</tr>
<tr>
<td>Brain 69</td>
<td>PCR</td>
<td>14/46</td>
<td>5/23</td>
<td></td>
<td>0.295 (P &lt; 0.0047, APOE ε4)</td>
<td>237</td>
</tr>
<tr>
<td>Brain 109</td>
<td>PCR</td>
<td>45/61</td>
<td>30/48</td>
<td>(P &lt; 0.0001, APOE ε4)</td>
<td>238</td>
<td></td>
</tr>
<tr>
<td>Brain 110</td>
<td>PCR</td>
<td>54/74</td>
<td>26/36</td>
<td>0.82</td>
<td>239, 240</td>
<td></td>
</tr>
<tr>
<td>Total brain</td>
<td>556</td>
<td>210/344</td>
<td>118/212</td>
<td>P = 0.2152 OR = 1.25</td>
<td>CI = 0.9–1.8</td>
<td></td>
</tr>
</tbody>
</table>

Number of Alzheimer cases with positive detection/number of Alzheimer cases analysed; Control, number of control cases with positive detection/number of control cases analysed. P, value of significance following Fischer test; OR, odds ratio; CI, 95% confidence interval values; +, positive; –, negative; AD, Alzheimer disease; CSF, cerebrospinal fluid; HSV-1, herpes simplex virus type-1; IHC, immunohistochemistry; ISH, in situ hybridisation; PCR, polymerase chain reaction; APOE ε4: epsilon 4 allele of apolipoprotein E.
Anti-HSV-1 antibodies as detected in the CSF by enzyme-linked immunosorbent assay (ELISA) were also significantly higher in AD patients than in younger controls, but without a significant difference between the AD and age-matched control groups (Ref. 242). Increased titres of HSV-1 IgGs, which characterise past infection, were observed in AD cases and age-matched controls, without a significant difference between the two groups (Refs 243, 244). In a large prospective study, in addition to HSV-1 IgG, the presence of IgM, which characterises active primary infection or reactivation of the infection, was also assessed in the sera of 512 elderly patients, initially free of dementia. During 14 years of follow-up, 77 AD cases were diagnosed. In contrast to IgG, IgM-positive subjects showed a significantly higher risk of developing AD, indicating that reactivation of HSV-1 seropositivity is correlated with AD (Ref. 245).

Other herpes viruses were also detected in the brain using PCR: human herpes virus 6 (HHV6) types A and B, herpes simplex virus type-2 (HSV-2) and cytomegalovirus (CMV). HHV6, HSV-2 and CMV were observed in 70%, 13% and 36% of AD patients and in 40%, 20% and 35% of controls, respectively. The differences between the groups were not statistically significant (Ref. 246).

In addition to CMV, a possible association between HLA-BW15 and AD has also been reported (Ref. 247). A recent study revealed that elderly subjects with high levels of antibody against CMV develop more severe cognitive decline over 4 years (Ref. 248) compared with controls.

The adenovirus early region 1A (E1A) gene and its expression using ISH and immunohistochemistry were analysed in five AD cases and in two controls. Reactive microglial cells in both AD (5/5) and control brain tissue (2/2) showed positive hybridisation and immunoreactive expression of adenovirus E1A, indicating a monocyte- or microglia-mediated entry of adenovirus into the central nervous system (CNS) (Ref. 249).

Borna disease virus (BDV) was linked to affective disorders and schizophrenia (Refs 139, 142). A few attempts have been made to analyse the prevalence of BDV antibodies and BDV p40 gene coding sequences in AD (Refs 250, 251, 252), which did not show an association (Table 3). Following Borna-virus-induced infection in APP(Tg2576) transgenic mice, a reduction of cortical and hippocampal Aβ deposits was observed (Ref. 253). One explanation is that the stimulation and activation of microglia might produce this effect.

The human immunodeficiency virus type-1 (HIV-1) (Ref. 254) is able to induce the biological hallmarks of AD; however, the virus is present in the brains of mostly young patients suffering from acquired immune deficiency syndrome (AIDS). The virus invades mostly macrophages and glial cells and the virus itself does not reproduce the pathological hallmarks of AD. However, by affecting immune defences, HIV-1 facilitates infection by various pathogens, including, among others, HSV-1, CMV, C. pneumoniae and spirochetes (Refs 255, 256, 257, 258).

**Correlates of infection risk and AD**

Based on the data available on the association of spirochetes, C. pneumoniae and HSV-1 with AD, contingency tables were used to analyse the strength of the association and the risk of infection in AD. In those studies where all types of spirochetes were detected using neutral techniques, spirochetes were observed in the brain in 90.1% (64/71) of AD cases and were absent in controls without any AD-type changes. This difference is significant (Table 1), and the association remains significant when cases where spirochetes were analysed in the blood are also included. The association between periodontal pathogen spirochetes and AD is also statistically significant. They were detected in the brain in 93.7% of AD cases and in 33.3% of controls. B. burgdorferi was about 13 times more frequent in AD cases than in controls, a statistically significant difference. It is noteworthy that B. burgdorferi was detected in all AD cases with a positive serology or where spirochetes were cultivated from the brain (Table 1). Taken together, in all studies where spirochetes or their specific species (periodontal *Treponema* spirochetes or *B. burgdorferi*) were detected in the brain, it can be concluded that the frequency of spirochetes is more than eight times higher in AD cases (90/131; 68.7%) than in controls (6/71; 8.41%). That spirochetes were cultivated from the brains of AD patients indicates that viable spirochetes are present in advanced stages of dementia. They can sustain persisting infection and inflammation and cause neuronal destruction (Ref. 148).
The frequency of *C. pneumoniae* was about five times higher in AD cases (60/125; 48%) than in controls (5/52; 9.6%). The difference remains significant when those cases where *C. pneumoniae* was detected in the CSF were also included (Table 1). That *C. pneumoniae* was cultivated from the brain (Refs 200, 213) and CSF (Ref. 202) and that replicative RBs were present in glial cells, neurons and pericytes in AD indicate that this microorganism is also present in a viable, active form in the brain in AD.

There is no significant difference between the frequency of HSV-1 detected in the brain in AD patients compared with age-matched control. However, a significant difference was observed between APOE ε4-positive and -negative AD carriers, as reported by several authors (Refs 236, 237, 259, 260), except for Beffert and colleagues (Refs 239, 240). A significant association of AD with ongoing or reactivated HSV-1 infection was reported (Ref. 245).

### Evidence for a causal role of pathogens in AD

Additional studies have brought further evidence in favour of a probable causal relationship between spirochetes, *C. pneumoniae*, HSV-1 and AD. Exposure of primary mammalian neuronal and glial cells to spirochetes, namely to *B. burgdorferi*, which can be cultivated and propagated in pure culture, generated thioflavin-S-positive and Aβ-immunoreactive amyloid plaques and tangle- and granulovacuolar-like formations in vitro (Refs 175, 261). In situ, in the spirochete-induced Aβ plaques, synchrotron infrared microspectroscopy analysis revealed the presence of a β-pleated sheet conformation (Ref. 261). Spirochete-induced increases in Aβ, APP and phosphorylated tau were all detected by western blot in infected cell cultures (Ref. 261). This additional experimental evidence indicates that spirochetes are able to induce an AD-type host reaction and reproduce the defining pathological and biological hallmarks of AD (Refs 175, 261). Similar in vitro studies performed on CNS organotypic cultures, which aim to replace in vivo experiments, showed identical results (Ref. 261). Reference *B. burgdorferi* spirochetes (strain B31) and those cultivated from the AD brain (strains ADB1 and ADB2) invaded neurons and glial cells and induced nuclear fragmentation in vitro, indicating that the spirochetes cultivated from the brains of AD patients are invasive and cause neuronal and glial damage and apoptosis (Refs 175, 261). Spirochetes occur in both extra- and intracellular locations. They invade neurons in vitro, in primary neuronal cultures (Refs 175, 261), in the cerebral cortex and in the trigeminal ganglia of AD patients (Refs 146, 147, 148, 149, 175, 183, 184, 261). Historical observations and illustrations showing that chronic spirochetal infection can reproduce the clinical, pathological and biological hallmarks of AD strongly support a causal relationship between spirochetal infection and AD (Refs 114, 115, 124). All these observations indicate that various types of spirochetes, including *B. burgdorferi* and several periodontal pathogen spirochetes, in an analogous way to *T. pallidum*, can cause dementia, cortical atrophy and the pathological and biological hallmarks of AD.

Astrocytes and microglia infected in vitro with *C. pneumoniae* display inclusions that are indistinguishable from those characteristic of active infection of the standard HEp-2 host cell line (Refs 214, 215). It was reported that chronic or persistent infection of CNS cells with *C. pneumoniae* can affect apoptosis in AD, in both a pro- and antiapoptotic manner (Refs 203, 214, 215). Furthermore, infection of BALB/c mice by intranasal inhalation of *C. pneumoniae* initiated Aβ1–42 deposits in the brain that resembled senile plaques (Ref. 262). Antibiotic treatment following *C. pneumoniae* infection limited the number of induced amyloid plaques in vivo (Ref. 263).

The glycoprotein B (gB) of HSV-1 has a highly homologous sequence to a fragment of Aβ (Ref. 264). Synthetic peptides derived from this region accelerate fibrillar aggregation of Aβ in vitro. They can self-assemble into fibrils, which are ultrastructurally indistinguishable from Aβ and are neurotoxic at a similar dose to Aβ. It was proposed that HSV-1 might act as a ‘seed’ for senile plaque formation (Ref. 265). It was also shown that HSV-1 is associated with APP during its anterograde transport, which might affect APP degradation and synaptic function (Ref. 265).

Exposure of cultured cells to HSV-1 results in increased intracellular Aβ levels in neurons and glial cells as analysed by immunocytochemistry.
ELISA and western blot. Tau phosphorylation was also observed at a number of sites that are phosphorylated in AD (Refs 266, 267, 268). It was suggested that the association of viral DNA and senile plaques is very likely to be causal, because HSV-1 is able to increase the level of Aβ in neurons of infected mice in vivo (Ref. 266).

**Evidence for underlying mechanisms**

**Sources and dissemination**

Spirochetes, *C. pneumoniae* and HSV-1 are all able to invade the brain (Fig. 3) and generate latent and persistent chronic infection (Refs 144, 145, 146, 147, 148, 149, 228, 229, 269). The strong neurotropism of spirochetes is well known (Ref. 167). In addition to haematogenous dissemination, spirochetes can spread through the lymphatic system and along nerve fibre tracts (Ref. 167). Periodontal invasive spirochetes were detected in the trigeminal ganglia and along the trigeminal nerve (Ref. 147). They might also propagate along the fila olfactoria and tractus olfactorius, which would enable them to reach the CSF, the septal and hippocampal regions in the earliest stages of the disease. This would be in harmony with the olfactory hypothesis (Refs 94, 95, 96) and the early involvement of the olfactory tract and bulb (Ref. 97).

Through infected circulating monocytes, *C. pneumoniae* can also spread by haematogenous dissemination and, by crossing the blood–brain barrier, infect the brain. *C. pneumoniae* is an upper respiratory tract pathogen and can reach the brain through the olfactory system (Ref. 95). Intranasal inhalation of *C. pneumoniae* initiated plaque-like Aβ$_{1-42}$ deposits in the brain in BALB/c mice, and *C. pneumoniae*-specific DNA was detected by PCR in the olfactory bulb in AD (Ref. 262).

HSV-1 infection might also reach the brain through the olfactory system, by infection of cranial and peripheral nerves and their ganglia and through haematogenous dissemination (Refs 270, 271). The virus can reside in the brain...
in a latent form and be reactivated by peripheral infection, stress or immunosuppression (Ref. 268).

**Neuroinflammation and TLR signalling**
Persisting, poorly degradable bacterial remnants in mammalian tissues act as chronic inflammatory stimuli (Refs 272, 273, 274). Lipopolysaccharides (LPSs), PGN and various bacterial lipoproteins elicit a variety of proinflammatory responses and might represent an important source of inflammation in AD. Complex interactions between the innate and adaptive immune systems have a major role in infection (Ref. 275). The functions of innate immunity allow host cells to recognise most microorganisms, execute proinflammatory defences and start adaptive immune responses.

Bacteria attach to host cells through a variety of cell-surface components, including surface amyloid proteins, which interact with host proteases (Refs 276, 277, 278, 279, 280, 281, 282, 283). Proteolysis of the extracellular matrix allows bacteria to penetrate the basement membrane and invade host cells.

It is the innate immune system that provides the first line of defence against microorganisms. Pattern recognition receptors (PRRs), such as Toll-like receptors (TLRs), recognise unique structures of invading microorganisms (Ref. 284). Patients with genetic defects related to signalling pathways activated by TLRs frequently suffer from severe recurrent infection (Refs 285, 286, 287, 288, 289). In the absence of TLRs, death from experimental sepsis is significantly enhanced (Ref. 287). Various bacteria, including spirochetes, activate TLR signalling and interact with CD14 (Refs 290, 291, 292). *T. pallidum* and *B. burgdorferi* or their synthetic membrane lipoproteins are major inflammatory mediators (Refs 293, 294) and activate both the classical and alternative complement pathways, which opsonise and kill pathogens without the need for antibody.

Complex interactions between pathogen-associated molecular patterns (PAMPs), PRRs and TLR signalling pathways have a major role in linking innate and adaptive immunity and maintaining pathogen-free host tissues (Ref. 275). TLRs activate two major signalling pathways (Fig. 4). The core pathway activated by most TLRs leads to the activation of transcription factor nuclear factor-kappa B (NF-kB) and the mitogen-activated protein kinases (MAPKs) p38 and Jun kinase (JNK). The second pathway is activated by TLR3 and TLR4 and results in the activation of both NF-κB and interferon regulatory factor-3 (IRF3), allowing the induction of another set of inflammatory genes, including the antiviral interferon-β gene (IFNB).

Activation of p38 MAPKs during bacterial infection was also shown to be crucial in the local production of cytokines such as IL-8 (Ref. 295) and in the development of effective immune responses in vivo (Ref. 296). Toxin-induced p38 MAPK activation requires pore formation and is inhibited by the relief of osmotic stress.

Pore-forming toxins are the most common class of bacterial protein toxins and are often important virulence factors (Ref. 297). Pore-forming bacterial toxins are typically oligomers of soluble, monomeric proteins or peptides, which form transmembrane channels. Channel formation in the membrane of targeted cells, which triggers cellular ion imbalance, is a widely used form of bacterial attack (Refs 298, 299). These pore-forming bacterial toxins generate calcium-dependent and lipid-mediated signalling on host cell surfaces, leading to a variety of events such as tyrosine phosphorylation (Ref. 300), actin rearrangement (Ref. 301), NF-κB activation (Ref. 302) and regulation of gene expression through histone modification (Ref. 303).

Mammals also use bacterial porin-like proteins such as perforins as part of their innate immune defences (Ref. 304). Aβ1–42 was shown to be an AMP that belongs to the innate immune system. Toxic oligomers of Aβ1–42 bind to lipid bilayers of bacterial membranes and enveloped viruses, triggering Ca²⁺ influx and bacteriolysis or viral destruction. Deregulation of the balance between host cell destruction by pathogens and pathogen destruction by the host immune systems will influence the outcome of infections.

The innate and alternative pathways through the common membrane attack complex (MAC, C5b9) cause bacteriolysis (Refs 305, 306, 307). Cellular and humoral components of the immune system reactions are both associated with AD (Refs 98, 99, 100, 101, 102). The adaptive immune system kills pathogens through the formation of specific antibodies directed against invading microorganisms. Monocytes, macrophages and microglia...
Pore-forming bacterial toxins and bacterial amyloids

Ca²⁺

Pore formation on host cell membrane

Cell membrane

Cytolysis, neuronal and glial cell destruction

Bacterial proliferation

Evasion

Bacterium

Antibodies

Gene expression cytokines

IL-1, IL-6, IL-8, IL-18, TNF-α, COX2, IFN-β

Gene expression B7.1- Naive T cells

IFN-responsive genes

Bacterium

Nucleus

IRF8

CREB

NF-κB

NF-γ-secretase

Increased Aβ

AMP function of Aβ

β-secretase

γ-secretase

Soluble oligomers, pore formation on bacterial lipid membrane

Aβ1-42

TLR3, TLR9

p38

IκB

JNK

Akt

Caspase1

NF-kB

MAPK

p38

eNOS

Akt

Complement, MAC

Antibodies

Bacterial antigen

Bacterial killing

Bacterium

Activation of innate and adaptive immune responses

Schematic representation of signalling pathways implicated in host–pathogen interactions in Alzheimer disease

Expert Reviews in Molecular Medicine © 2011 Cambridge University Press

Figure 4. Schematic representation of signalling pathways implicated in host–pathogen interactions in Alzheimer disease. Pattern recognition receptors (PRRs) recognise conserved structural components of microorganisms, called pathogen-associated molecular patterns (PAMPs) or ligands, which include peptidoglycan (PGN), lipoteichoic acid (LTA), flagellin (FLA), bacterial lipoprotein (BLP) and nucleic acid structures, such as bacterial CpG DNA or viral RNA, unique to bacteria and viruses. Lipopolysaccharide (LPS) is recognised following its binding to lipoprotein binding protein (LBP). Only Toll-like receptors (TLRs) have a cytoplasmic domain for signal transduction. Plasma-membrane-localised TLRs include TLR1, TLR2, TLR4, TLR5, TLR6 and TLR10, whereas endosomal TLRs include TLR3, TLR7, TLR8 and TLR9. TLR9 is responsible for the recognition of CpG islands of bacterial DNA. Complex interactions between pathogen-associated molecular patterns (PAMPs), pattern recognition receptors (PRRs) and TLR signalling pathways have a major role in linking innate and adaptive immunity and maintaining pathogen-free host tissues. Mammals use antimicrobial peptides (AMPs) as part of their innate immune defences to destroy invading pathogens. In contrast, in a similar way, pore-forming bacterial surface proteins are also able to destroy host cells. Evasion of pathogens by destruction by the host immune defences will result in chronic persistent infection and host cell destruction. APP, amyloid precursor protein; Aβ, amyloid beta; CD14, cluster of differentiation 14; NF-κB, nuclear factor-kappa B; MALP2, mycoplasma diacylated lipopeptide 2; p38 MAPK, mitogen-activated protein kinase; JNK, c-Jun kinase; MAC, membrane attack complex; MD2, lymphocyte antigen 96; Akt, serine/threonine protein kinase Akt1; IRF, interferon regulatory factor; IL, interleukin; TNF, tumour necrosis factor; COX2, cyclooxygenase 2; IFN, interferon, CREB, cAMP response element binding.
participate in both the innate and adaptive immune responses. When activated, they secrete chemokines and cytokines and express various proinflammatory molecules needed for the efficient removal of pathogens and damaged cells.

Neuroinflammatory responses that include activation of glia with marked elevation of cytokine expression, in particular elevation of IL-1, are observed in AD, in Down syndrome fetuses and children before plaque formation, and also in HIV infection (Refs 99, 308, 309). IL-1 directs both the in vivo (Ref. 310) and in vitro synthesis of APP (Ref. 311), thus favouring senile plaque formation in AD. IL-1 upregulation of ApoE promotes ApoE-mediated induction of APP (Ref. 312) and MAPK-p38-mediated tau phosphorylation, in part by upregulation of MAPK-p38 synthesis and activation and by favouring the formation of neurofibrillary tangles (Refs 313, 314, 315). IL-1 also influences neurotransmission because it increases the synthesis and activation of AChE (Ref. 316) and induces neuron loss by increasing caspase 1 (IL-1β cleavage enzyme) activity (Refs 317, 318). Microglial activation by APP and release of secreted APP (sAPP) modulated by apolipoprotein E also have an important role in the degenerative process of AD (Refs 313, 319). Activation of microglia with TLR2, TLR4 and TLR9 ligands increases Aβ ingestion in vitro (Ref. 320). Furthermore, stimulation of the immune system through TLR9 in APP transgenic (Tg2576) mice reduces Aβ deposition (Ref. 321).

**Evasion and establishment of latent and chronic infection**

The ability of spirochetes and *C. pneumoniae* to evade destruction by host immune systems and establish chronic infection is well known. HSV-1 can also remain in a latent state and persist throughout life in human tissues. In the latent state, the viral genome is present, but no viral particles are produced. Viral gene expression during latency is limited to one locus – the gene encoding the latency-associated transcript (Ref. 151).

Pathogens use a broad range of strategies to overcome antigenic recognition, complement lysis and phagocytosis. Blockade of the complement cascade or acquisition of host-derived complement inhibitors results in their evasion from complement lysis. This allows microbial survival and proliferation even in immune-competent hosts. Complement-resistant strains of *B. burgdorferi* possess five complement regulatory acquiring surface proteins, which bind host complement inhibitors (Refs 307, 322) and a CD59-like molecule (Refs 322, 323). A fragment of HSV-1 glycoprotein C (gC) shares sequence similarity with host complement receptor 1 (CR1), showing that viruses can also escape from attack by the MAC. Bacteria and viruses protect themselves from destruction by the host adaptive immune system. *B. burgdorferi* induces IL-12, a cytokine recently recognised to be critical for driving cellular responses towards the Th1 subset of T helper cells (Refs 293, 324). This shift retards antibody induction by Th2 cells against bacteria. These various ways of evasion allow bacteria to survive and proliferate in host tissues and sustain chronic infection.

**Iron and nitric oxide**

Bacterial cell wall components, including LPSs and PGNs, are highly resistant to degradation by mammalian enzymes and persist indefinitely in mammalian tissues. During chronic exposure, bacteria and bacterial debris accumulate in infected host tissues, sustaining chronic inflammation and slowly progressive cell damage (Refs 272, 273, 274, 325, 326). Bacteria, LPSs and PGNs have a variety of biological actions in mammals (Ref. 327). They not only are inflammatory cytokine inducers and activators of complement pathways, but they also affect vascular permeability (Ref. 328), induce nitric oxide and free radicals, inhibit DNA synthesis, and cause apoptosis and cellular damage (Ref. 329).

Macrophage regulation of immune surveillance involves iron depletion (Refs 330, 331, 332). Lactoferrin, which is similar in structure to transferrin, has a role in natural defence mechanisms in mammals and is upregulated in neurodegenerative disorders. Lactoferrin exerts its anti-inflammatory action by inhibiting hydroxyl radical formation. This antioxidant property prevents DNA damage (Ref. 329). By contrast, free iron abolishes the bactericidal effects of serum and strongly enhances infection and bacterial virulence (Refs 329, 330, 331, 332). Iron has been shown to increase the formation of reactive oxygen intermediates, resulting in
lipid peroxidation and subsequent oxidative damage of proteins and nucleic acids (Refs 330, 331, 332). By affecting T-cell generation, iron also influences antigen-specific cellular responses, T-cell functions and the production of proinflammatory cytokines by macrophages (Ref. 333). Iron, which has a fundamental role in infection, also accumulates in senile plaques in AD (Refs 330, 334, 335, 336).

Activation of macrophages and other host cells by bacteria or LPS causes inducible nitric oxide synthase (iNOS) synthesis, which in turn generates substantial amounts of nitric oxide from the amino acid l-arginine (Ref. 332). Nitric oxide is a critical component in the clearance of bacterial, viral, fungal and parasitic infections (Ref. 337). In a mouse model, genetic disruption of iNOS was associated with a significantly higher risk of dissemination and mortality of infection (Ref. 338). Pathogens have also evolved a broad array of strategies to limit nitric oxide production (Refs 338, 339, 340), which might contribute to their evasion from host immune responses (Ref. 340). Nitric oxide also has a central role in chronic degenerative diseases, including AD (Ref. 341).

**Amyloidogenesis**

Amyloidogenesis is the aggregation of soluble proteins into detergent-insoluble filamentous structures about 10 nm wide and 0.1–10 μm long. These amyloid fibrils have distinct biochemical and biophysical properties, including resistance to proteinase K treatment, β-sheet structure and affinity for binding thioflavin S and Congo Red.

Chronic bacterial infections (e.g. rheumatoid arthritis, leprosy, tuberculosis, syphilis, osteomyelitis) are frequently associated with amyloid deposition. Cortical and vascular amyloid deposition in the atrophic form of general paresis, caused by a spirochete (*T. pallidum*), as in AD, corresponds to Aβ.

On the basis of previous observations, it has been suggested that amyloidogenic proteins might be an integral part of spirochetes and can contribute to Aβ deposition in AD (Ref. 146). It was shown that the BH9(9–10) peptide on a β-hairpin segment of *B. burgdorferi* OspA forms amyloid fibrils in vitro that are similar to those in human amyloidosis (Ref. 342). Recent observations indicate that amyloid proteins constitute a previously overlooked integral part of the cellular envelope of many bacteria (Refs 343, 344, 345, 346). Amyloid fibril formation not only results in toxic aggregates, but also provides biologically functional molecules (Refs 343, 344, 347). Bacterial amyloids are involved in bacterial cell–cell interactions, in their attachment to inert solid surfaces, and in spore and biofilm formation (Ref. 347). Microbial amyloids, through interaction with host proteases, also contribute to bacterial virulence, to colonisation of the host and to invasion of host cells.

Bacterial LPSs and PGNs are used worldwide to generate in vitro and in vivo experimental inflammation and amyloidosis (Ref. 348). LPSs induce Aβ accumulation, increased APP levels and hyperphosphorylation of tau in vitro and in vivo (Refs 261, 349, 350, 351). Increased APP mRNA in response to LPS was also detected in the basal forebrain and hippocampus of the rat (Ref. 349). Aβ deposition occurs in the brains of rats chronically infused with LPSs (Ref. 349). In a triple-transgenic mouse model of AD, repeated challenges with LPSs were shown to exacerbate CNS inflammation and to cause increased tau phosphorylation (Ref. 351).

**Genetic factors**

Host responses to bacterial infections are genetically controlled. Promoter polymorphisms in the genes of proinflammatory cytokines are associated with susceptibility to infection (Ref. 352). Tumour necrosis factor alpha (TNF-α) is a critical mediator of host defence against infection. Polymorphisms in the gene encoding TNF-α might determine a strong cell-mediated immune response or a weak or absent cellular response, which reflects the genetic variability in cytokine production (Refs 352, 353). In the absence of cell-mediated immune responses, the microorganism can spread freely and accumulate in infected host tissues (Ref. 354). Accordingly, in *Mycobacterium leprae* infection, two distinct phenotypes can be distinguished: tuberculous leprosy and the lepromatous leprosy. In the tuberculous or paucibacillary form, there is strong inflammatory infiltration and the number of microorganisms is low. Conversely, in the lepromatous or bacillary form, the inflammatory infiltrates are poor or absent and the number of *M. leprae* is high. A similar polarity in host reactions – the infiltrative form with strong cell-mediated...
immune responses and few spirochetes versus the atrophic form, lacking lymphoplasmocytic infiltrates but with numerous spirochetes – occurs in response to T. pallidum and B. burgdorferi infection (Refs 114, 115, 118, 149). The influence of TNF-α polymorphism on spirochetal infections has also been demonstrated by others (Ref 355).

Class II major histocompatibility genes influence host immune responses to bacterial and viral infections. The major histocompatibility complex phenotype of the antigen-presenting cell can modulate Th1-like versus Th2-like cell activity against M. leprae and other pathogens. In general, it has been acknowledged that human leukocyte antigen (HLA) DR isotypes are associated with a protective response, whereas DQ isotypes are associated with the multidisciplinary lepromatous form with a limited cellular response. HLA gene polymorphism is a dominant marker of susceptibility to various infections, including B. burgdorferi infection (Ref. 356). The important role of the HLA system in controlling cell-mediated responses suggests that differences in HLA haplotypes could contribute to the wide spectrum of immune responses observed in leprosy and in other infections (Ref. 357). It is noteworthy that TNF-α and HLA polymorphisms, which are risk factors for infection, substantially influence the risk of AD (Refs 61, 358, 359, 360, 361, 362).

Association between AD pathology and IL-1β expression patterns (Ref. 363), and between disease risk and IL-1β gene polymorphisms, has been reported (Refs 62, 364). Genetic variation in the expression of microbial PRRs, including TLRs, and CD14 gene polymorphisms predispose to various infections and are also associated with AD (Refs 365, 366).

Genetic mutations in APP, PS1 and PS2 are related to the processing of APP (Ref. 39). Because APP has an important role in the regulation of immune system reactions and in T-cell differentiation (Refs 16, 17, 18), genetic defects in such genes should also result in increased susceptibility to infection.

APOE ε4 enhances the expression of inflammatory mediators (Refs 367, 368) and has a modulatory function in susceptibility to infection by various bacteria, viruses and protozoa (Refs 367, 368, 369, 370, 371, 372). APOE genotyping of three AD cases, where B. burgdorferi was detected and cultivated from the brain, showed that two of them were APOE ε4 carriers. The low number of cases does not allow any conclusion for an eventual link between spirochetal infection and the APOE ε4 allele (Ref. 149). Sixty-four per cent of AD cases with positive C. pneumoniae PCR had at least one APOE ε4 allele (Ref. 207). ISH and quantitative real-time PCR analyses indicated that the number of C. pneumoniae-infected cells and the bacterial load in affected brain regions of APOE ε4 carriers in AD were significantly higher compared with those lacking that allele (Ref. 200). Furthermore, HIV-1-infected subjects carrying the APOE ε4 allele have higher recorded levels of dementia (Ref. 369), and the ε4 allele has also been shown to modulate HSV-1 infection (Refs 240, 259, 260, 371).

**Outstanding research questions and conclusions**

The analysis of all positive and negative data available in the literature on the association of pathogens with AD indicates a statistically significant association between various types of spirochetes, C. pneumoniae and AD. There is no significant difference between the frequency of HSV-1 in AD cases compared with age-matched controls. However, several authors found a significant difference between the frequencies of HSV-1 in APOE ε4 carriers and noncarriers. The occurrence of positive anti-HSV-1 IgM was reported to be a risk factor for AD (for a recent review, see Ref. 373).

Lesions that are similar to senile plaques, neurofibrillary tangles and neuropil threads, and granulocytic degeneration, accumulation of Aβ, increased APP levels and phosphorylation of tau have all been induced by exposure of mammalian neuronal and glial cells and CNS organotypic cultures to spirochetes. Aβ-positive plaques were induced by inhalation of C. pneumoniae in mice in vivo, and exposure to HSV-1 increased the Aβ level and produced tau phosphorylation in neurons in vitro and in vivo.

Through TLRs and other PRRs, pathogens or their toxic components induce gene expression and activation of proinflammatory molecules by host cells. Both the classical and alternative complement pathways are activated in AD. MAC(C5b-9), which is intended to lyse bacteria or encapsulated viruses, and activated microglia that are designed to clean up debris and foreign
bacteria are both associated with cortical AD lesions.

Evasion of pathogens from host defence reactions results in sustained infection and inflammation. The microorganisms and their toxic components can be observed in affected brains, along with host immunological responses. Spirochetes, C. pneumoniae and HSV-1 disseminate from the primary site of infection to the brain usually through systemic infection. As in syphilis, systemic infection and inflammation precede the development of dementia by years or decades. Detection of infection in its early, peripheral stage can hamper its dissemination to the CNS and prevent dementia. Consequently, peripheral infections can have a role in the initiation and progression of neurodegeneration in AD (Refs 146, 374, 375, 376). Worsening of peripheral and systemic infection will deteriorate CNS involvement. One example is periodontitis, which is caused mostly by Gram-negative bacteria, including periodontal spirochetes, which represents a risk factor for AD (Refs 156, 377).

It is important to consider that several types of spirochetes and several types of pathogens can occur in AD. Coinfection of B. burgdorferi with various periodontal spirochetes (Ref. 147) or with T. pallidum (Ref. 378) is well documented. T. pallidum frequently coinfected with other bacteria and herpes viruses in syphilis (Ref. 167). In Lyme disease, coinfection of B. burgdorferi with C. pneumoniae and HSV-1, which are also associated with AD, can be observed. Coinfection by several microorganisms can accelerate the degenerative process, exacerbate CNS damage and worsen dementia.

An infectious origin of AD is in harmony with recent observations showing that Aβ belongs to the group of AMPs, which are potent, broad-spectrum bactericides targeting Gram-negative and Gram-positive bacteria, enveloped viruses, fungi and protozoans (Ref. 31). Aβ has the capacity to associate with lipid bilayers of bacterial cell membranes and to exert antimicrobial activity by membrane permeabilisation and by alteration of calcium homeostasis (Refs 31, 379). The microtubule-binding site of tau protein also exhibits antimicrobial properties (Ref. 380).

Inflammation has a primordial role in the elimination of invading pathogens and infected host cells. If infection is eradicated, it helps the healing process. Some proinflammatory molecules, such as cytokine IL-1β, in addition to their harmful effects, have a beneficial and protective effect (Ref. 381). Therefore, long-term use of anti-inflammatory drugs alone might weaken the elimination of pathogens and facilitate their evasion, survival and slowly progressive proliferation. Combined antibiotic, antiviral and anti-inflammatory therapy is suggested as the treatment of choice.

In conclusion, the data available indicate that infectious agents can initiate the degenerative process in AD, sustain chronic inflammation, and lead to progressive neuronal damage and amyloid deposition. The accumulated knowledge, views and hypotheses proposed to explain the pathogenesis of AD fit well with an infectious origin of the disease. The outcome of infection is determined by the genetic predisposition of the patient, by the virulence and biology of the infecting agent, and by various environmental factors, such as exercise, stress and nutrition.

More attention and support is needed for this emerging field of research. Infection starts long before the manifestation of dementia; therefore, an adequate treatment should start early. Because antibacterial, antiviral and anti-inflammatory therapy is available, as in syphilis, one could prevent and eradicate dementia. The effect on the suffering of patients and on the reduction of healthcare costs would be considerable.

Acknowledgements and funding
I am grateful to all those colleagues and friends who strongly supported my work on this emerging field of research during the last two decades. They all contributed, in different ways, to the realisation of this work. I thank B. Balin, A. Hudson, J. Hudson and R. Itzhaki, who have reviewed and completed data related to their field of research on C. pneumoniae and HSV-1, and R. Kraftsik for his help with the statistical analysis. This work was funded by the Prevention Alzheimer International Foundation, Switzerland. I am grateful to the peer reviewers and to the editors of the journal, who significantly contributed with their constructive advice and remarks.

References


Redlich, E. (1898) Über miliare Sklerose der Hirnrinde bei seniler Atrophie. Jahrbuch für Psychiatrie und Neurologie 17, 208-216


Ledoux, S. et al. (1993) Amyloid precursor protein in peripheral mononuclear cells is up-regulated with cell activation. Journal of Immunology 150, 5566-5575


Rudel, T. et al. (1996) Modulation of Neisseria porin (PorB) by cytosolic ATP/GTP of target cells: parallels between pathogen accommodation and mitochondrial endosymbiosis. Cell 85, 391-402
Emerging roles of pathogens in Alzheimer disease

Accession information: doi:10.1017/S1462399411002006; Vol. 13; e30; September 2011
© Cambridge University Press 2011

http://www.expertreviews.org/ in molecular medicine

Ayalà, P. et al. (2005) The pilus and porin of Neisseria gonorrhoeae cooperatively induce Ca(2+) transients in infected epithelial cells. Cellular Microbiology 7, 1736-1748
Müller, A. et al. (1999) Neisserial porin (PorB) causes rapid calcium influx in target cells and induces apoptosis by the activation of cysteine proteases. EMBO Journal 18, 339-352
Suzuki, N. et al. (1994) An increased percentage of long amyloid beta protein secreted by familial amyloid beta protein precursor (beta APP717) mutants. Science 264, 1336-1340
Scheuner, D. et al. (1996) Secreted amyloid beta-protein similar to that in the senile plaques of Alzheimer’s disease is increased in vivo by the presenilin 1 and 2 and APP mutations linked to familial Alzheimer’s disease. Nature Medicine 2, 864-870

Downloaded from https://www.cambridge.org/core. IP address: 54.70.40.11, on 03 Jul 2019 at 05:08:04, subject to the Cambridge Core terms of use, available at https://www.cambridge.org/core/terms. doi:10.1017/S1462399411002006; Vol. 13; e30; September 2011 © Cambridge University Press 2011
42/1-40 ratio in vitro and in vivo. Neuron 17, 1005-1013

58 Tomita, T. et al. (1997) The presenilin 2 mutation (N141I) linked to familial Alzheimer disease (Volga German families) increases the secretion of amyloid beta protein ending at the 42nd (or 43rd) residue. Proceedings of the National Academy of Sciences of the United States of America 94, 2025-2030


60 Roses, A.D. (1994) Apolipoprotein E is a relevant susceptibility gene that affects the rate of expression of Alzheimer’s disease. Neurobiology of Aging 2 (Suppl), 165-167


64 Perry, G. et al. (1993) Immunocytochemical evidence that the beta-protein precursor is an integral component of neurofibrillary tangles of Alzheimer’s disease. American Journal of Pathology 143, 1586-1593


71 Martins, R.N. et al. (1986) Increased cerebral glucose-6-phosphate dehydrogenase activity in Alzheimer’s disease may reflect oxidative stress. Journal of Neurochemistry 46, 1042-1045


78 Jellinger, K. et al. (1990) Brain iron and ferritin in Parkinson’s and Alzheimer’s diseases. Journal of Neural Transmission. Parkinson’s Disease and Dementia Section 2, 327-340


Emerging roles of pathogens in Alzheimer disease

Alzheimer's disease? Neurological Research 15, 146-153
98 McGeer, P.L. et al. (1987) Reactive microglia in patients with senile dementia of the Alzheimer type are positive for the histocompatibility glycoprotein HLA-DR. Neuroscience Letters 79, 195-200
99 Griffin, W.S. et al. (1989) Brain interleukin 1 and S-100 immunoreactivity are elevated in Down syndrome and Alzheimer disease. Proceedings of the National Academy of Sciences of the United States of America 86, 7611-7615
Emerging roles of pathogens in Alzheimer disease

Accession information: doi:10.1017/S1462399411002006; Vol. 13; e30; September 2011 © Cambridge University Press 2011

http://www.expertreviews.org/

112 Hübner, A.H. (1908) Zur Histopathologie der senilen Hirnrinde. Archives of Psychiatry and Neurology 46, 598-609
117 Rizzo, C. (1931) Ricerche sulle spirochete nel cervello dei paralitici. Riv Patol Nerv 37, 797-814
121 Bonfiglio, F. (1908) Di speciali reperti in un caso di probabile sifilide cerebrale. Deutsche Pathologische Gesellschaft 34, 196-206
126 Laitinen, K. et al. (1997) Chlamydia pneumoniae infection induces inflammatory changes in the aortas of rabbits. Infection and Immunity 65, 4832-4835
137 Micillo, E. et al. (2000) Respiratory infections and asthma. Allergy 61 (Suppl), 42-45
138 Marttila, R.J. et al. (1977) Viral antibodies in the sera from patients with Parkinson disease. European Neurology 15, 25-33
Emerging roles of pathogens in Alzheimer disease

Accession information: doi:10.1017/S1462399411002006; Vol. 13; e30; September 2011 © Cambridge University Press 2011


166 Dewhirst, F.E. et al. (2000) The diversity of periodontal spirochetes by 16S rRNA analysis. Oral Microbiology and Immunology 15, 196-202


Emerging roles of pathogens in Alzheimer disease

Accession information: doi:10.1017/S1462399411002006; Vol. 13; e30; September 2011

© Cambridge University Press 2011

172 Riviere, G.R. et al. (1991) Pathogen-related oral spirochetes from dental plaque are invasive. Infection and Immunity 59, 3377-3380
Emerging roles of pathogens in Alzheimer disease


201 Gérard, H.C. et al. (2006) Chlamydomphila (Chlamydia) pneumoniae in the Alzheimer’s brain. FEMS Immunology and Medical Microbiology 48, 355-366


203 Appelt, D.M. et al. (2008) Inhibition of apoptosis in neuronal cells infected with Chlamydomphila (Chlamydia) pneumoniae. BMC Neuroscience 9, 13


211 MacIntyre, A. et al. (2003) Chlamydia pneumoniae infection promotes the transmigration of monocytes through human brain endothelial cells. Journal of Neuroscience Research 71, 740-750


Emerging roles of pathogens in Alzheimer disease

Accession information: doi:10.1017/S1462399411002006; Vol. 13; e30; September 2011

© Cambridge University Press 2011


228 Jamieson, G.A. et al. (1992) Herpes simplex virus type 1 DNA is present in specific regions of brain from aged people with and without senile dementia of the Alzheimer type. Journal of Pathology 167, 365-368


231 Sequiera, L.W. et al. (1979) Detection of herpes-simplex viral genome in brain tissue. Lancet 2, 609-612


236 Itzhaki, R.F. et al. (1997) Herpes simplex virus type 1 in brain and risk of Alzheimer’s disease. Lancet 349, 241-244


247 Renzo, E.B. et al. (1979) Possible association of Alzheimer’s disease with HLA-BW15 and cytomegalovirus infection. Lancet 1, 1238


249 Matsuse, T. et al. (1994) Immunohistochemical and in situ hybridisation detection of adenovirus early region 1A (E1A) gene in the microglia of human brain tissue. Journal of Clinical Pathology 47, 275-277

250 Igata, T. et al. (1997) Dementia and Borna disease virus. Dementia and Geriatric Cognitive Disorders 9, 24-25

251 Yamaguchi, K. et al. (1999) Detection of borna disease virus-reactive antibodies from patients with psychiatric disorders and from horses by electrochemiluminescence immunoassay. Clinical and Diagnostic Laboratory Immunology 6, 696-700


253 Stahl, T. et al. (2006) Viral-induced inflammation is accompanied by beta-amyloid plaque reduction in brains of amyloid precursor protein transgenic...


270 Boggian, I. et al. (2000) Asymptomatic herpes simplex type 1 virus infection of the mouse brain. Journal of Neurovirology 6, 303-313

271 Valyi-Nagy, T. et al. (2000) Herpes simplex virus type 1 latency in the murine nervous system is associated with oxidative damage to neurons. Virology 278, 309-321


275 Palaniyar, N. et al. (2002) Pulmonary innate immune proteins and receptors that interact with gram-positive bacterial ligands. Immunobiology 205, 575-594


279 Ben Nasr, A. et al. (1996) Assembly of human contact phase proteins and release of bradykinin at the surface of curli-expressing Escherichia coli. Molecular Microbiology 20, 927-935


281 Sjöbring, U., Pohl, G. and Olsén, A. (1994) Plasminogen, absorbed by Escherichia coli...
expressing curli or by Salmonella enteritidis expressing thin aggregative fimbriae, can be activated by simultaneously captured tissue-type plasminogen activator (t-PA). Molecular Microbiology 14, 443-445


284 Crack, P.J. and Bray, P.J. (2007) Toll-like receptors in the brain and their potential roles in neuropathology. Immunology and Cell Biology 85, 476-480

285 Lorenz, E. et al. (2002) Relevance of mutations in the TLR4 receptor in patients with gram-negative septic shock. Archives of Internal Medicine 162, 1028-1032


291 Sellati, T.J. et al. (1998) Treponema pallidum and Borrelia burgdorferi lipoproteins and synthetic lipopeptides activate monocyteic cells via a CD14-dependent pathway distinct from that used by lipopolysaccharide. Journal of Immunology 160, 5455-5464


293 Radolf, J.D. et al. (1995) Characterization of outer membranes isolated from Borrelia burgdorferi, the Lyme disease spirochete. Infection and Immunity 63, 2154-2163


296 van den Blink, B. et al. (2001) p38 mitogen-activated protein kinase inhibition increases cytokine release by macrophages in vitro and during infection in vivo. Journal of Immunology 166, 582-587


298 Gekara, N.O. et al. (2007) The multiple mechanisms of Ca(2+) signalling by listeriolysin O, the cholesterol-dependent cytolysin of Listeria monocytogenes. Cellular Microbiology 9, 2008-2021


Accession information: doi:10.1017/S1462399411002006; Vol. 13; e30; September 2011

© Cambridge University Press 2011

Downloaded from https://www.cambridge.org/core. IP address: 54.70.40.11, on 03 Jul 2019 at 05:08:04, subject to the Cambridge Core terms of use, available at https://www.cambridge.org/core/terms. https://doi.org/10.1017/S1462399411002006
305 Blanco, D.R. et al. (1999) Immunization with Treponema pallidum outer membrane vesicles induces high-titer complement-dependent treponemical activity and aggregation of T. pallidum outer membrane proteins (TROMPs). Journal of Immunology 163, 2741-2746


310 Sheng, J.G. et al. (1996) In vivo and in vitro evidence supporting a role for the inflammatory cytokine interleukin-1 as a driving force in Alzheimer pathogenesis. Neurobiology of Aging 17, 761-766

311 Goldgaber, D. et al. (1989) Interleukin 1 regulates expression and phosphorylation of neurofilament protein which colonize humans. Infection and Immunity 61, 4535-4539


313 Li, Y. et al. (2003) Interleukin-1 mediates pathological effects of microglia on tau phosphorylation and on synaptophysin synthesis in cortical neurons through a p38-MAPK pathway. Journal of Neuroscience 23, 1605-1611


318 Li, Y. et al. (2004) Microglial activation by uptake of fDNA via a scavenger receptor. Journal of Neuroimmunology 147, 50-55


326 Lehman, T.J. et al. (1983) Polyarthritis in rats following the systemic injection of Lactobacillus casei cell walls in aqueous suspension. Arthritis and Rheumatism 26, 1259-1265


334 Goodman, L. (1953) Alzheimer's disease; a clinicopathologic analysis of twenty- three cases with a theory on pathogenesis. Journal of Nervous and Mental Disease 118, 97-130


343 Otzen, D. and Nielsen, P.H. (2008) We find them here, we find them there: functional bacterial amyloid. Cellular and Molecular Life Sciences 65, 910-927


345 Larsen, P. et al. (2007) Amyloid fiber adhesins are abundant in natural biofilms. Environmental Microbiology 9, 3077-3090


353 Shaw, M.A. et al. (2001) Association and linkage of leprosy phenotypes with HLA class II and tumour necrosis factor genes. Genes and Immunity 2, 196-204


355 Marangoni, A. et al. (2004) Production of tumor necrosis factor alpha by Treponema pallidum, Borrelia burgdorferi s.l., and Leptospira interrogans in isolated rat Kupffer cells. FEMS Immunology and Medical Microbiology 40, 187-191

356 Steere, A.C., Dwyer, E. and Winchester, R. (1990) Association of chronic Lyme arthritis with HLA-
Emerging roles of pathogens in Alzheimer disease


369 Corder, E.H. et al. (1998) HIV-infected subjects with the E4 allele for APOE have excess dementia and peripheral neuropathy. Nature Medicine 4, 1182-1184


Features associated with this article

Figures
Figure 1. Distribution of spirochetes in the atrophic form of general paresis and in the frontal cortex of an Alzheimer disease (AD) patient with Lyme neuroborreliosis.
Figure 2. Spirochetes detected in the frontal cortex of neuropathologically confirmed Alzheimer disease cases.
Figure 3. Sources and dissemination of pathogens associated with Alzheimer disease.
Figure 4. Schematic representation of signalling pathways implicated in host–pathogen interactions in Alzheimer disease.

Tables
Table 1. Detection of spirochetes in AD.
Table 2. Detection of *Chlamydia pneumoniae* and other bacteria in AD.
Table 3. Detection of HSV-1 in AD.

Citation details for this article